Matthew Moyer, MS, MD
Professor, Medicine
Biography
Dr. Moyer concentrates both clinically and in research on interventional endoscopy, gastrointestinal cancer, and the research and development of innovative endoscopic techniques and devices in these areas.
Since graduating his fellowship in 2009 and joining the nationally recognized interventional endoscopy group, Dr. Moyer has been heavily involved in developing the quality and volume of interventional endoscopy and endoscopic surgical services offered at Penn State Health. Dr. Moyer’s clinical practice centers on pancreatic and biliary disease, inflammatory bowel disease and interventional endoscopy including ERCP, EUS, EUS-guided interventional techniques, EMR, ESD, chemoablation of cystic lesions and transluminal endoscopic surgery. Dr. Moyer also periodically staffs the free medical clinic of the Bethesda Mission in Harrisburg.
Research and development are the hallmarks of the interventional endoscopy group. Dr. Moyer has authored over 75 major publications, presented at numerous national meetings and received numerous awards in this area including the 2017 American College of Gastroenterology Governors Award for Excellence in Clinical Research and the 2016 Lockheed Martin Design Excellence Award.
Although Dr. Moyer’s research team has published on multiple techniques in recent years, their most significant current projects include the multicenter, randomized, prospective CHARM II trial, which is further developing the innovation of EUS-guided chemoablation of pancreatic mucinous cystic tumors. Pancreatic cysts are precancerous in a majority of cases and this innovative procedure presents a minimally invasive option to eliminate these precursors to pancreatic adenocarcinoma in appropriately selected cases. CHARM II is funded by the National Institutes of Health and is an active collaboration between Penn State Health and Indiana University. The trial is currently enrolling patients.
Along with Charles E. Dye, MD, this innovative research team is also responsible for the development of the Chimera Project, a joint effort with the Penn State Bioengineering to develop a minimally invasive EUS-guided ablation device for solid abdominal and mediastinal tumors.
Dr. Moyer is currently funded by an NIH R01 grant and the Anna Fakadej Research and Development Fund.
Research Highlights
![[object Object]](https://images.ctfassets.net/u5e6iuf5dlnc/1ODyQdUXaA9kaA0iql8Pz4/add96ac72e3ad24dc7e85ca4ab0dfef5/moyer-lab-figure-1.jpg)
![[object Object]](https://images.ctfassets.net/u5e6iuf5dlnc/7ndOHehtxcGOTOzzyDBjVn/3c798709cb80c8f6d4bd84b2c2628008/Moyer-lab-figure-2jpg.jpg)
![[object Object]](https://images.ctfassets.net/u5e6iuf5dlnc/4j3cDgEiebRILROCT8K0Li/d261de1b260d8ffb262a6c2bc6efca33/Chimera-poster-moyer-lab-scaled.jpg)
The Chimera Project is a joint effort with Penn State Bioengineering to develop a minimally invasive EUS-guided ablation device for solid abdominal and mediastinal tumors.
The alcohol-free, EUS-guided, cyst ablation process: The FNA needle is introduced into the center of the cystic lesion, followed by near complete aspiration of mucinous fluid from all compartments, leaving a small rim of fluid around the needle tip to prevent damaging the cyst wall. This is followed subsequently filling the cyst with an equal volume of the CHARM chemotherapy ablation admixture.
Before and after MRI and MRCP images of a patient with a 3.6cm mucinous (precancerous) pancreatic cyst participating in the CHARM Trial. Images on the right show complete resolution of the cyst after EUS-guided chemoablation using the CHARM Protocol.